Obecabtagene autoleucel
Details of the Drug
- Generic Name:
- Obecabtagene autoleucel
- Drug Type:
- CD19-directed genetically modified autologous T cell immunotherapy
- How the Drug is Given:
Intravenous infusion
- Names:
- Aucatzyl®
- Obecabtagene autoleucel
Indications and Usage
Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Side effects needing medical attention
The most common (non-laboratory) adverse reactions are: cytokine release syndrome (CRS), infections - pathogen unspecified, musculoskeletal pain, viral infections, fever, nausea, bacterial infectious disorders, diarrhea, febrile neutropenia, ICANS, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.